Sutro Biopharma (FRA:S09) Gross-Profit-to-Asset % : 11.93% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Sutro Biopharma Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Sutro Biopharma's annualized Gross Profit for the quarter that ended in Mar. 2024 was €47.9 Mil. Sutro Biopharma's average Total Assets over the quarter that ended in Mar. 2024 was €401.4 Mil. Therefore, Sutro Biopharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 11.93%.

Sutro Biopharma Gross-Profit-to-Asset % Historical Data

The historical data trend for Sutro Biopharma's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sutro Biopharma Gross-Profit-to-Asset % Chart

Sutro Biopharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

22.83

15.11

17.49

18.64

34.56

Sutro Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															13.18	10.07	15.22	99.77	11.93

Competitive Comparison of Sutro Biopharma's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Sutro Biopharma's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sutro Biopharma's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sutro Biopharma's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Sutro Biopharma's Gross-Profit-to-Asset % falls into.

Sutro Biopharma Gross-Profit-to-Asset % Calculation

Sutro Biopharma's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	140.971	/	( (384.155	+	431.665)	/ 2 )
	=	140.971	/	407.91
	=	34.56 %

Sutro Biopharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	47.868	/	( (431.665	+	371.13)	/ 2 )
	=	47.868	/	401.3975
	=	11.93 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Sutro Biopharma Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Sutro Biopharma's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sutro Biopharma (FRA:S09) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sutro Biopharma Inc (FRA:S09) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

STRO:USA S09:Germany

Address

111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.sutrobio.com

Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Sutro Biopharma (FRA:S09) Headlines

No Headlines